◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › RPRX

Royalty Pharma Plc (RPRX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-07-22

Royalty Pharma Plc (RPRX) operates in the BIOTECHNOLOGY industry and is headquartered in New York, United States with about 100 employees. Its market capitalization is roughly $34 billion. In the fiscal year ended 2025-12-31, RPRX reported $2.4B in revenue and $771M in net income.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.

Interactive charts & full statements → Open the RPRX valuation workbench →

RPRX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$2.4B	$2.4B	$2.3B	$2.4B	$2.2B	$2.3B	$2.1B	$1.8B	$1.8B	$1.6B	$1.9B	$1.7B	$0M	—	—	—	$0M	—	—	—	—
Gross Profit	$2.4B	$2.4B	$2.3B	$2.4B	$2.2B	$2.3B	$2.1B	$1.8B	$1.8B	$1.6B	$1.9B	$1.7B	$0M	—	—	—	—	—	—	—	—
Gross Margin %	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	—	—	—	—	—	—	—	—	—
Operating Income (EBIT)	$1.7B	$1.6B	$1.3B	$1.5B	$307M	$1.4B	$1.6B	$2.6B	$1.4B	$940M	$723M	$794M	($33M)	—	—	—	—	—	—	—	—
Operating Margin %	67.9%	65.6%	57.1%	63.4%	13.7%	62.5%	75.2%	144.6%	76.0%	58.8%	38.5%	48.1%	—	—	—	—	—	—	—	—	—
Net Income	$828M	$771M	$859M	$1.1B	$43M	$620M	$975M	$2.3B	$1.4B	$1.2B	$566M	$581M	($33M)	—	—	—	—	—	—	—	—
Net Margin %	33.9%	32.4%	38.0%	48.2%	1.9%	27.1%	45.9%	129.4%	76.8%	75.7%	30.1%	35.2%	—	—	—	—	—	—	—	—	—
EBITDA	$1.7B	$1.6B	$1.6B	$1.9B	$424M	$1.4B	$1.9B	$2.8B	$1.8B	$1.6B	$1.1B	$862M	—	—	—	—	—	—	—	—	—
Earnings Per Share (EPS)	$1.48	$1.38	$1.45	$1.88	$0.08	$1.49	$2.60	$6.63	$3.89	$3.42	$0.93	$0.96	$-0.09	—	—	—	—	—	—	—	—
Shares Outstanding (M)	560M	560M	594M	603M	565M	415M	375M	354M	354M	354M	607M	607M	354M	354M	354M	354M	354M	354M	354M	354M	354M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RPRX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$631M	$622M	$609M	$579M	$568M	$594M	$565M	$537M
Gross Profit	$629M	$622M	$609M	$579M	$568M	$594M	$565M	$537M
Gross Margin %	99.8%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income (EBIT)	$632M	$388M	$427M	$210M	$534M	$362M	$735M	$270M
Operating Margin %	100.3%	62.4%	70.1%	36.3%	94.0%	60.9%	130.2%	50.2%
Net Income	$295M	$214M	$288M	$30M	$238M	$208M	$544M	$102M
Net Margin %	46.8%	34.4%	47.3%	5.2%	41.9%	35.1%	96.3%	19.0%
EBITDA	$563M	$451M	$525M	$159M	$499M	$400M	$873M	$243M
Earnings Per Share (EPS)	$0.53	$0.38	$0.52	$0.05	$0.41	$0.35	$0.92	$0.17
Shares Outstanding (M)	560M	560M	560M	562M	578M	589M	593M	597M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RPRX Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$2.7B	$2.5B	$2.8B	$3.0B	$2.1B	$2.0B	$2.0B	$1.7B	$1.6B	$1.4B	($16M)	($25M)	($29M)	—	—	—	—	—	—	—	—
Capital Expenditures (CapEx)	$1M	$0M	$0M	$2.1B	$2.0B	$1M	$2.2B	$1.7B	$270M	$2.3B	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	$2.7B	$2.5B	$2.8B	$872M	$103M	$2.0B	($162M)	($54M)	$1.3B	($872M)	($16M)	($25M)	($29M)	—	—	—	—	—	—	—	—
FCF Margin %	108.7%	104.7%	122.3%	37.0%	4.6%	88.1%	-7.6%	-3.0%	75.1%	-54.6%	-0.8%	-1.5%	—	—	—	—	—	—	—	—	—
Dividends Paid	$387M	$378M	$376M	$358M	$333M	$285M	$397M	$739M	$814M	$735M	—	—	—	—	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RPRX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$761M	$827M	$703M	$364M	$596M	$743M	$704M	$658M
Capital Expenditures (CapEx)	$0M	$0M	$1M	$0M	$0M	$0M	$833M	$747M
Free Cash Flow (FCF)	$761M	$827M	$702M	$364M	$596M	$743M	($129M)	($88M)
FCF Margin %	120.6%	133.0%	115.1%	62.9%	104.9%	125.1%	-22.9%	-16.5%
Dividends Paid	$104M	$94M	$95M	$93M	$95M	$94M	$94M	$95M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RPRX Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$19.8B	$19.6B	$18.2B	$16.4B	$16.8B	$17.5B	$21.1B	$12.4B	$11.4B	$11.4B	$10.5B	$10.8B	$47M	$79M	$27M	$6M	$4M	$3M	$23M	$28M	$8M
Cash & Cash Equivalents	$586M	$619M	$929M	$477M	$1.7B	$1.5B	$1.0B	$246M	$1.9B	$1.4B	$1.7B	$1.7B	$47M	$76M	$24M	$5M	$3M	$2M	$19M	$2M	$1M
Total Liabilities	$9.9B	$9.9B	$7.9B	$6.3B	$7.3B	$7.3B	$6.1B	$6.3B	$6.8B	$6.9B	$6.0B	$6.1B	$3M	$4M	$4M	$1M	$1M	$2M	$7M	$4M	$4M
Total Debt (Short + Long-Term)	$9.0B	$9.0B	$7.6B	$6.1B	$7.1B	$14.0B	$6.1B	$6.2B	$6.5B	$281M	$173M	$184M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$6.9B	$6.5B	$6.9B	$6.5B	$5.6B	$10.2B	$15.0B	$6.1B	$4.5B	$4.5B	$4.4B	$4.7B	$44M	$75M	$23M	$5M	$3M	$1M	$16M	$24M	$4M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RPRX viewer.

Other Companies in BIOTECHNOLOGY

RVMD · Revolution Medicines Inc — $40 billion
ALNY · Alnylam Pharmaceuticals Inc — $36 billion

← RPM All stocks RPT →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.